Singapore markets closed

Straits Times Index
3,323.38
+0.18(+0.01%)
S&P 500
5,241.69
-25.26(-0.48%)
Dow
38,055.10
-386.44(-1.01%)
Nasdaq
16,826.17
-94.41(-0.56%)
Bitcoin USD
68,492.77
+911.77(+1.35%)
CMC Crypto 200
1,432.56
-23.31(-1.60%)

BPMC Oct 2024 95.000 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

19.90

0.00

(0.00%)

As of 09:32AM EDT. Market open.

PR Newswire
Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting
Blueprint Medicines Corporation (Nasdaq: BPMC) today announced updated data from the ongoing Phase 1 dose escalation portion of the VELA clinical trial of BLU-222, an investigational, highly selective and potent CDK2 inhibitor, in combination with ribociclib and fulvestrant in patients with hormone-receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. The data, which mark the first promising clinical results for a CDK2 inhibitor in combination with an app
Simply Wall St.
Blueprint Medicines (NASDAQ:BPMC) pulls back 3.5% this week, but still delivers shareholders notable 85% return over 1 year
If you want to compound wealth in the stock market, you can do so by buying an index fund. But investors can boost...
Zacks
Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand have been highlighted in this Industry Outlook article.